Trump’s 50% India tariffs threaten MedTech exports, disrupt supply chains

Trump’s 50% tariffs on Indian goods take effect from 12:01 am eastern daylight time on August 27, 2025. Shipments that left India before this effective time and are cleared by September 17, 2025, are exempt from the additional duty.

Trump’s 50% tariffs have delivered a severe blow to India’s medical devices sector, resulting in a dramatic loss of price competitiveness for Indian exporters in their second-largest market. With about $287.7 million worth of medical devices exported to the US in 2023-24—including major items like endoscopes, orthopaedic implants, MRI equipment, catheters, and ECG machines—industry players now face a tariff burden that matches or exceeds those imposed on leading importer nations like China and the European Union.

Previously, Indian medical devices often enjoyed low or zero-duty status, but the new tariffs bring rates up to the 50% mark. The impact is particularly acute for low-value, high-volume consumables, where slim margins leave little room for absorbing cost hikes. Exporters fear US buyers will swiftly pivot to sourcing from Southeast Asian competitors—Indonesia, Vietnam, and others—whose tariffs remain near 19–20%. As orders are expected to be cancelled or shifted away, MSME exporters (who make up a substantial portion of the sector) could see sharp declines in revenue and employment. Larger Indian manufacturers are reportedly considering diversifying away from the US to Europe, West Asia, or near-shoring supply chains under alternate trade regimes.

Industry leaders have called the move “short-sighted and strategically misguided,” warning that it not only risks significant job losses and investment setbacks in India but, ironically, could also increase health care costs and device shortages for American patients by disrupting established supply chains. Further complicating the outlook, non-tariff barriers and high US FDA regulatory costs remain key hurdles for Indian exporters, who now face both tariff and compliance headwinds. Calls for urgent dialogue, policy action, and bilateral negotiations are growing as firms weigh whether the US market remains viable—or whether a painful market realignment is now inevitable.
MB Bureau